ImmuCell Corp (ICCC) stock
ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 13/303% above fair value
$11.25−0.08 (-0.71%)
Close on Nov 18, 2026Market cap $102.18MP/E 140.6Yield –
ImmuCell gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
ImmuCell's gross profit for the twelve months ending Jun 30, 2026 was $12.37M, up 16.8% year over year. For fiscal 2025 it was $11.45M, up 44.1% from the year before. Over ten years it grew 6.2% a year on average. The highest annual figure on record is $11.45M in fiscal 2025.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $11.45M | +44.1% |
| FY2024 | Dec 31, 2024 | $7.94M | +105.2% |
| FY2023 | Dec 31, 2023 | $3.87M | -49.4% |
| FY2022 | Dec 31, 2022 | $7.65M | -11.6% |
| FY2021 | Dec 31, 2021 | $8.66M | +26.1% |
| FY2020 | Dec 31, 2020 | $6.86M | +1.8% |
| FY2019 | Dec 31, 2019 | $6.74M | +29.8% |
| FY2018 | Dec 31, 2018 | $5.19M | -0.5% |
| FY2017 | Dec 31, 2017 | $5.22M | -3.7% |
| FY2016 | Dec 31, 2016 | $5.42M | -13.3% |
| FY2015 | Dec 31, 2015 | $6.25M | +40.5% |
| FY2014 | Dec 31, 2014 | $4.45M | +45.4% |
| FY2013 | Dec 31, 2013 | $3.06M | +0.2% |
| FY2012 | Dec 31, 2012 | $3.05M | +8.5% |
| FY2011 | Dec 31, 2011 | $2.81M | +22.2% |
| FY2010 | Dec 31, 2010 | $2.30M | -4.0% |
| FY2009 | Dec 31, 2009 | $2.40M | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $2.44M | -13.5% |
| Q1 FY2026 | Mar 31, 2026 | $4.66M | +38.9% |
| Q4 FY2025 | Dec 31, 2025 | $2.91M | +2.8% |
| Q3 FY2025 | Sep 30, 2025 | $2.36M | +49.2% |
| Q2 FY2025 | Jun 30, 2025 | $2.82M | +129.0% |
| Q1 FY2025 | Mar 31, 2025 | $3.35M | +46.1% |
| Q4 FY2024 | Dec 31, 2024 | $2.83M | – |
| Q3 FY2024 | Sep 30, 2024 | $1.58M | +25.0% |
| Q2 FY2024 | Jun 30, 2024 | $1.23M | +17.9% |
| Q1 FY2024 | Mar 31, 2024 | $2.30M | +663.1% |
| Q4 FY2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023 | Sep 30, 2023 | $1.27M | -31.4% |
| Q2 FY2023 | Jun 30, 2023 | $1.04M | -38.9% |
| Q1 FY2023 | Mar 31, 2023 | $300.78K | -90.3% |
| Q4 FY2022 | Dec 31, 2022 | $992.18K | -61.3% |
| Q3 FY2022 | Sep 30, 2022 | $1.85M | -23.7% |
| Q2 FY2022 | Jun 30, 2022 | $1.71M | -17.7% |
| Q1 FY2022 | Mar 31, 2022 | $3.10M | +93.7% |
| Q4 FY2021 | Dec 31, 2021 | $2.56M | +58.0% |
| Q3 FY2021 | Sep 30, 2021 | $2.42M | +40.4% |
| Q2 FY2021 | Jun 30, 2021 | $2.07M | +61.6% |
| Q1 FY2021 | Mar 31, 2021 | $1.60M | -28.3% |
| Q4 FY2020 | Dec 31, 2020 | $1.62M | -11.8% |
| Q3 FY2020 | Sep 30, 2020 | $1.72M | +18.7% |
| Q2 FY2020 | Jun 30, 2020 | $1.28M | +2.8% |
| Q1 FY2020 | Mar 31, 2020 | $2.24M | +1.6% |
| Q4 FY2019 | Dec 31, 2019 | $1.84M | +31.6% |
| Q3 FY2019 | Sep 30, 2019 | $1.45M | +52.6% |
| Q2 FY2019 | Jun 30, 2019 | $1.25M | -16.0% |
| Q1 FY2019 | Mar 31, 2019 | $2.20M | +61.9% |
| Q4 FY2018 | Dec 31, 2018 | $1.40M | +15.2% |
| Q3 FY2018 | Sep 30, 2018 | $950.97K | +1.6% |
| Q2 FY2018 | Jun 30, 2018 | $1.49M | +61.4% |
| Q1 FY2018 | Mar 31, 2018 | $1.36M | -36.8% |
| Q4 FY2017 | Dec 31, 2017 | $1.21M | -0.5% |
| Q3 FY2017 | Sep 30, 2017 | $935.85K | -22.3% |
| Q2 FY2017 | Jun 30, 2017 | $921.35K | – |
| Q1 FY2017 | Mar 31, 2017 | $2.15M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.22M | – |
| Q3 FY2016 | Sep 30, 2016 | $1.20M | – |
See a number that looks wrong?